PMID- 30397594
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240403
IS  - 2296-9209 (Print)
IS  - 2296-9179 (Electronic)
IS  - 2296-9179 (Linking)
VI  - 4
IP  - 2
DP  - 2018 Oct
TI  - Attenuated Mismatch Negativity in Attenuated Psychosis Syndrome Predicts 
      Psychosis: Can Galantamine-Memantine Combination Prevent Psychosis?
PG  - 71-74
LID - 10.1159/000488797 [doi]
AB  - Although first proposed in 1987, early diagnosis and intervention of psychotic 
      disorders has only recently become a priority in the field. The interest in 
      clinical high risk (CHR) for psychosis skyrocketed after attenuated psychosis 
      syndrome (APS) was added to the DSM-5. There is evidence that in individuals with 
      APS, attenuated mismatch negativity (MMN: functioning of the auditory sensory 
      memory system) is a robust biomarker that can predict transition to psychosis. 
      The underlying pathophysiological mechanism of MMN is via the interaction of 
      N-methyl-D-aspartate (NMDA) and alpha-7 nicotinic acetylcholine (alpha-7nACh) 
      receptors. Galantamine is an acetylcholinesterase inhibitor and a positive 
      allosteric modulator of the alpha-7nACh receptors. Memantine is an NMDA receptor 
      antagonist. Memantine has been shown to enhance MMN in people with schizophrenia. 
      Although no studies with galantamine have measured MMN, encenicline, an alpha-7 
      nicotinic partial agonist, increased MMN in people with schizophrenia. MMN has 
      been suggested as a potential biomarker with the galantamine-memantine 
      combination for the treatment of neuropsychiatric disorders. Hence, the 
      galantamine-memantine combination may enhance MMN, thereby preventing CHR to 
      psychosis. With no treatments available, randomized controlled trials are 
      warranted with the galantamine-memantine combination to delay or prevent 
      conversion to psychosis in individuals with CHR.
FAU - Koola, Maju Mathew
AU  - Koola MM
AD  - Department of Psychiatry and Behavioral Sciences, George Washington University 
      School of Medicine and Health Sciences, Washington, District of Columbia, USA.
LA  - eng
PT  - Journal Article
DEP - 20180607
PL  - Switzerland
TA  - Mol Neuropsychiatry
JT  - Molecular neuropsychiatry
JID - 101649121
PMC - PMC6206967
OTO - NOTNLM
OT  - Attenuated psychosis syndrome
OT  - Biomarker
OT  - Clinical high risk
OT  - Galantamine
OT  - Kynurenic acid
OT  - Memantine
OT  - Mismatch negativity
EDAT- 2018/11/07 06:00
MHDA- 2018/11/07 06:01
PMCR- 2019/10/01
CRDT- 2018/11/07 06:00
PHST- 2018/01/16 00:00 [received]
PHST- 2018/03/26 00:00 [accepted]
PHST- 2018/11/07 06:00 [entrez]
PHST- 2018/11/07 06:00 [pubmed]
PHST- 2018/11/07 06:01 [medline]
PHST- 2019/10/01 00:00 [pmc-release]
AID - mnp-0004-0071 [pii]
AID - 10.1159/000488797 [doi]
PST - ppublish
SO  - Mol Neuropsychiatry. 2018 Oct;4(2):71-74. doi: 10.1159/000488797. Epub 2018 Jun 
      7.